Cooper Companies (NASDAQ:COO) Director Lawrence Erik Kurzius Buys 10,000 Shares of Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Kurzius purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were purchased at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the acquisition, the director directly owned 31,099 shares in the company, valued at $1,708,268.07. The trade was a 47.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Monday, September 14th, Lawrence Kurzius purchased 10,000 shares of Cooper Companies stock. The shares were purchased at an average cost of $53.91 per share, with a total value of $539,100.00.

Cooper Companies Price Performance

Shares of Cooper Companies stock opened at $53.78 on Friday. The company’s fifty day simple moving average is $70.23 and its two-hundred day simple moving average is $68.77. The Cooper Companies, Inc. has a 12-month low of $51.01 and a 12-month high of $89.83. The firm has a market cap of $10.23 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 2.22 and a beta of 0.82. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts expect that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies declared that its board has approved a share repurchase plan on Wednesday, September 9th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On Cooper Companies

Several hedge funds and other institutional investors have recently modified their holdings of COO. Root Financial Partners LLC lifted its position in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 162 shares in the last quarter. Avalon Trust Co purchased a new stake in Cooper Companies in the second quarter worth about $25,000. SJS Investment Consulting Inc. raised its stake in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after buying an additional 187 shares during the period. Elevation Wealth Partners LLC raised its stake in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after buying an additional 375 shares during the period. Finally, Continuum Advisory LLC bought a new position in shares of Cooper Companies in the second quarter worth about $30,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Lawrence Kurzius purchased 10,000 shares for approximately $549,300, increasing his position by 47.4%. Other directors, including Paul Keel and Walter Rosebrough Jr., also recently bought shares. The purchases may provide a modest confidence signal from insiders after the selloff. Insider purchase report
• Neutral Sentiment: Jana Partners is pressing Cooper to replace its chief executive and pursue an urgent overhaul, citing “chronic underperformance.” The activist campaign could create a catalyst for strategic change, but it also increases leadership and execution uncertainty. Wall Street Journal activist report
• Negative Sentiment: Cooper’s latest quarterly results beat adjusted EPS expectations, $1.15 versus $1.12, but revenue of approximately $1.07 billion missed the $1.10 billion consensus. Management also reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 and revenue guidance to $4.23–$4.25 billion, reflecting weaker contact-lens demand.
• Negative Sentiment: Reports that U.S. distributors are reducing channel inventories have raised concerns about near-term sales and whether the weakness reflects temporary destocking or softer underlying demand. Inventory destocking report
• Negative Sentiment: Pomerantz, Bragar Eagel & Squire, and Levi & Korsinsky announced investigations into potential securities claims. These notices do not establish wrongdoing, but they add legal and headline risk. Analysts have also lowered their consensus price target to about $72.27. Pomerantz investigation

Analyst Ratings Changes

A number of research analysts have issued reports on COO shares. Piper Sandler downgraded shares of Cooper Companies from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $86.00 to $59.00 in a research report on Thursday, September 10th. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research report on Wednesday, May 27th. Zacks Research lowered shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday, September 11th. Wells Fargo & Company set a $61.00 price target on shares of Cooper Companies and gave the company an “equal weight” rating in a research report on Thursday, September 10th. Finally, Wall Street Zen downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.